InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021
First regulatory approvals to start the phase III study CONCLUDE“We will initiate patient recruitment when the clinics are up and running again after the summer as the healthcare situation has started to normalise,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period April – June 2021 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –42.6 (–15.6) million · Result after tax amounted to SEK –42.6 (–15.6) million, corresponding to SEK –0.08 per share (–0.07) before and after dilution · Cash flow from operating activities amounted to SEK –53.